nevirapine has been researched along with didanosine in 151 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 60 (39.74) | 18.2507 |
| 2000's | 60 (39.74) | 29.6817 |
| 2010's | 30 (19.87) | 24.3611 |
| 2020's | 1 (0.66) | 2.80 |
| Authors | Studies |
|---|---|
| Balzarini, J; Chen, F; De Clercq, E; He, Y; Pannecouque, C; Sun, G; Wang, Y | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Balzarini, J; Maurin, JK; Orzeszko, A; Orzeszko, B | 1 |
| Balzarini, J; Chen, FE; De Clercq, E; Pannecouque, C; Xiong, YZ | 1 |
| Balzarini, J; Maurin, JK; Orzeszko, A; Orzeszko-Krzesińska, B | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Bachmann, MH; Fessel, WJ; Kagan, RM; Mitsuya, Y; Shafer, RW; Shahriar, R; Varghese, V | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Azas, N; Casano, G; Dumètre, A; Hutter, S; Pannecouque, C; Robin, M | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, W; Chen, X; De Clercq, E; Li, D; Li, X; Liu, X; Pannecouque, C; Tian, Y; Zhan, P | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Balzarini, J; Chen, FE; Chen, WX; Daelemans, D; De Clercq, E; He, QQ; Pannecouque, C; Wu, HQ; Yan, ZH | 1 |
| Balzarini, J; Chen, X; De Clercq, E; Li, Z; Liu, H; Liu, X; Pannecouque, C; Xie, Z; Zhan, P; Zhang, L; Zhao, T | 1 |
| Costa, J; Dumontet, V; Leyssen, P; Litaudon, M; Neyts, J; Nothias-Scaglia, LF; Pannecouque, C; Paolini, J; Retailleau, P; Roussi, F | 1 |
| Chen, W; De Clercq, E; Liu, X; Liu, Z; Pannecouque, C; Zhan, P | 1 |
| Chen, FE; Chen, WX; Daelemans, D; De Clercq, E; He, QQ; Pannecouque, C; Wu, HQ; Yao, J | 1 |
| Balzarini, J; Chen, W; De Clercq, E; Fu, L; Huang, B; Li, C; Liu, H; Liu, T; Liu, X; Pannecouque, C; Sun, Y; Yu, M; Zhan, P | 1 |
| Ashok, P; Balzarini, J; Chander, S; Murugesan, S; Pannecouque, C | 1 |
| Chen, W; De Clercq, E; Fu, L; Huang, B; Li, C; Li, X; Liang, X; Liu, H; Liu, T; Liu, X; Pannecouque, C; Sun, Y; Zhan, P | 1 |
| Girard-Valenciennes, E; Grondin, I; Leyssen, P; Litaudon, M; Neyts, J; Olivon, F; Palenzuela, H; Pannecouque, C; Roussi, F | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, X; Daelemans, D; De Clercq, E; Huang, B; Kang, D; Li, W; Liu, X; Meng, Q; Pannecouque, C; Zhan, P | 1 |
| Bhatt, HG; Pannecouque, C; Patel, BD; Patel, SB | 1 |
| Chizhov, AO; Geisman, AN; Khandazhinskaya, AL; Kochetkov, SN; Naesens, L; Novikov, MS; Ozerov, AA; Pannecouque, C; Seley-Radtke, KL; Valuev-Elliston, VT | 1 |
| Bingöl Özakpınar, Ö; De Clercq, E; Küçükgüzel, İ; Kulabaş, N; Özsavcı, D; Pannecouque, C; Tatar, E | 1 |
| Buckheit, RW; Cushman, M; Hartman, TL; Hoshi, A; Okazaki, M; Pannecouque, C; Sakamoto, T; Takayama, J; Xuan, M | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Chen, Z; Daelemans, D; De Clercq, E; Huang, B; Li, W; Liu, H; Liu, X; Pannecouque, C; Sun, S; Wang, X; Zhan, P | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Connell, EV; Hsu, MC; Richman, DD | 1 |
| Brennan, TM; Bridges, CG; Leyda, JP; Taylor, DL; Tyms, AS | 1 |
| Barry, DW; Pennington, KN; Rooney, J; St Clair, MH | 1 |
| Bechtel, LJ; Chow, YK; D'Aquila, RT; Eron, JJ; Hirsch, MS; Kaplan, JC; Merrill, DP | 1 |
| Rennie, J | 1 |
| Cohen, J | 1 |
| Kellam, P; Kemp, SD; Larder, BA | 1 |
| Jäger, H | 1 |
| Basgoz, N; D'Aquila, RT; Fischl, MA; Hirsch, MS; Hughes, MD; Johnson, VA; Liou, SH; Myers, M; Niu, M; Sommadossi, JP; Timpone, J | 1 |
| Anderson, B; Farley, M; Fox, C; Luzuriaga, K; Mueller, BU; Pizzo, PA; Schwartzentruber, DJ; Sei, S; Sullivan, JL; Tudor-Williams, G; Venzon, DJ | 1 |
| Charpiot, B; Datema, R; Hincenbergs, M; Kaneshima, H; Linquist, V; McCune, JM; Moreno, MB; Rabin, L; Seifert, J; Warren, S | 1 |
| Baba, M; Hashimoto, KI; Okamoto, M; Shigeta, S; Tsunoda, R | 1 |
| Hirschel, B; Rutschmann, O | 1 |
| Iversen, AK; Merigan, TC; Shafer, RW; Winters, MA | 1 |
| Bryson, Y; Cort, S; Krogstad, P; Lamson, M; Luzuriaga, K; Robinson, J; Stechenberg, B; Sullivan, JL | 1 |
| Basgoz, N; Bremer, JW; D'Aquila, RT; Elbeik, T; Erice, A; Fischl, MA; Hirsch, MS; Hughes, MD; Johnson, VA; Kuritzkes, DR; Scott, WA; Spector, SA | 1 |
| Eisen, JA; Katzenstein, DA; Merigan, TC; Shafer, RW | 1 |
| Collins, DO; Sakamoto, A | 1 |
| Alaeus, A; Albert, J; Cox, S; Palmer, S | 1 |
| Arranz, ME; Balzarini, J; De Clercq, E; Declercq, R; Desmyter, J; Diaz, JA; Esnouf, R; Ingate, ST; Jonckheere, H; Pannecouque, C; Schmit, JC; Van Meervelt, L; Vandamme, AM; Vega, S; Witvrouw, M | 1 |
| Conway, B; Cooper, D; Hall, D; Harris, M; Lange, JM; Montaner, JS; Myers, M; Reiss, P; Robinson, P; Smith, D; Vella, S; Wainberg, MA | 1 |
| Conway, B; Cooper, D; Dohnanyi, C; Hall, DB; Lange, J; Montaner, JG; Myers, M; Reiss, P; Vella, S | 1 |
| Harrigan, PR; Harris, M; Mo, T; Montaner, JS | 1 |
| Conway, B; Cooper, D; Hall, D; Harris, M; Lange, J; Montaner, JS; Myers, M; Raboud, JM; Rae, S; Reiss, P; Robinson, P; Vella, S; Wainberg, MA | 2 |
| Saag, MS; Schooley, RT | 1 |
| Chan, KC; Ho, TT; Lee, SS; Wong, KH | 1 |
| Balfour, HH; Erice, A; Fischl, MA; Henry, K; Hirsch, MS; Kahn, JO; Kenton, A; Kmack, A; Liou, SH; Martinez, A; Phair, J; Tierney, C | 1 |
| D'Aquila, RT; Fischl, MA; Hirsch, MS; Hughes, MD; Johnson, VA; Myers, M; Sheiner, LB; Sommadossi, JP; Zhou, XJ | 1 |
| Clay, PG; Rathbun, RC; Slater, LN | 1 |
| Haubrich, R; Richman, D | 1 |
| Alberici, F; Andreotti, M; Bucciardini, R; Cargnel, A; De Rienzo, B; Fiaccadori, F; Floridia, M; Fragola, V; Francisci, D; Galluzzo, CM; Giannini, G; Grillone, W; Leoncini, F; Nigra, E; Ortona, L; Piazza, M; Pirillo, MF; Ricciardulli, D; Scalzini, A; Tomino, C; Tumietto, F; Vella, S; Weimer, LE | 1 |
| Claessen, FA; Hall, D; Hamann, D; Kauffmann, RH; Koopmans, PP; Kroon, ED; Kroon, FP; Lange, JM; Miedema, F; Montaner, JS; Otto, SA; Pakker, NG; Reiss, P; Roos, MT; Schellekens, PT; Sprenger, HG; ten Napel, CH; van der Ende, ME; Weigel, HM; Wit, FW | 1 |
| Brown, AJ; D'Aquila, RT; Günthard, HF; Johnson, VA; Kuritzkes, DR; Richman, DD; Wong, JK | 1 |
| Temesgen, Z; Wright, AJ | 1 |
| Brown, AJ; D'Aquila, RT; Hanna, GJ; Hazelwood, JD; Johnson, VA; Kuritzkes, DR; Richman, DD; Savara, AV | 1 |
| Carlebach, A; Gute, P; Haberl, A; Miller, V; Nisius, G; Staszewski, S | 1 |
| Allavena, C; Arvieux, C; Auger, S; Breux, JP; Francois, C; Garre, M; Hascoet, C; Perre, P; Raffi, F; Reliquet, V; Rozenbaum, W | 1 |
| Bucciardini, R; Fragola, V; Harrigan, PR; Montaner, JS; Raboud, JM; Rae, S; Ricciardulli, D; Vella, S | 1 |
| Allende, MC; Belloso, WH; Benetucci, JA; Cahn, PE; Davey, RT; Emery, S; Lane, HC; Lasala, MC; Law, MG; Lopardo, G; Losso, MH; Nelson, E; Salomon, H; Saracco, M | 1 |
| Ahmed, PS; Bedard, J; Bowlin, TL; Chambers, P; Clarke, J; Kelly, LA; Rando, RF; Taylor, DL; Tyms, AS; Wood, LJ | 1 |
| Andreotti, M; Binelli, A; Bucciardini, R; Floridia, M; Fragola, V; Galluzzo, MC; Giannini, G; Pirillo, MF; Ricciardulli, D; Tomino, C; Vella, S; Weimer, LE | 1 |
| Badia, X; Benavides, A; Coma, A; López Lavid, C; Pinto, JL | 1 |
| Beijnen, JH; Hoetelmans, RM; Kwakkelstein, MO; Lange, JM; Meenhorst, PL; Mulder, JW; Reiss, P; van Heeswijk, RP; Veldkamp, AI; Wit, FW | 1 |
| Aranda, M; Arrizabalaga, J; Cruceta, A; Dalmau, D; Ferrer, E; Gallart, T; García, F; Gatell, JM; Gomez-Sirvent, JL; Knobel, H; Miró, JM; Pumarola, T; Romeu, J; Sambeat, MA; Segura, F | 1 |
| Andreotti, M; Bucciardini, R; Floridia, M; Fragola, V; Galluzzo, CM; Giannini, G; Marzi, M; Massella, M; Mirra, M; Pirillo, MF; Ricciardulli, D; Tomino, C; Vella, S; Weimer, LE; Wu, AW | 1 |
| Arvieux, C; Bellein, V; Besnier, JM; Breux, JP; Ferré, V; Garré, M; Hascoet, C; May, T; Molina, JM; Perré, P; Raffi, F; Raguin, G; Reliquet, V; Rozenbaum, W; Zucman, D | 1 |
| Bosch García, R; Márquez Solero, M; Palacios Muñoz, R; Santos González, J | 1 |
| Genka, I; Kikuchi, Y; Oka, S; Tachikawa, N; Teruya, K; Yamamoto, Y; Yasuoka, A; Yasuoka, C | 1 |
| Moore, T; Ware, AJ | 1 |
| James, JS | 1 |
| Mascolini, M | 1 |
| Bowersox, J | 1 |
| Doepel, L; Folkers, G | 1 |
| MacDougall, DS | 1 |
| Beijnen, JH; Cooper, DA; Hall, D; Hoetelmans, RM; Lange, JM; Montaner, JS; Reiss, P; Veldkamp, AI; Vella, S; Weverling, GJ | 1 |
| Conway, B; Cooper, D; Curry, R; Hall, D; Harris, M; Lange, JM; Montaner, JS; Reiss, P; Robinson, P; Vella, S; Wainberg, MA | 1 |
| Carlebach, A; Gute, P; Haberl, A; Miller, V; Rottmann, C; Staszewski, S | 1 |
| Cahn, P; Federico, A; Kijak, G; Montaner, JS; Ochoa, C; Perez, H; Salomon, H; Zala, C | 1 |
| Flexner, C; Gandhi, R | 1 |
| Fan, B; Stewart, JT | 1 |
| Arnedo, M; Capon, A; Cruceta, A; Gallart, T; Garcia, F; Gatell, JM; Mestre, G; Miro, JM; Plana, M; Pumarola, T; Vidal, C | 1 |
| Baldanti, F; Galloni, D; Gerna, G; Lilleri, D; Piccinini, G; Seminari, E | 1 |
| Oka, S; Teruya, K | 1 |
| Das, P | 1 |
| Gerstoft, J; Katzenstein, TL; Kirk, O; Lundgren, JD; Mathiesen, L; Nielsen, H; Obel, N; Pedersen, C | 1 |
| Chang, WH; Yang, X; Zheng, YH | 1 |
| Carroll, H; Conlon, V; Green, A; Green, DC; Green, R; Jefferson, R; Jordan, WC; Tolbert, L; Yemofio, F | 1 |
| Boyle, BA | 1 |
| Cardellach, F; Casademont, J; García-Viejo, MA; Gatell, JM; López, S; Martínez, E; Milinkovic, A; Miró, O; Nunes, V; Pedrol, E; Rodríguez-Santiago, B; Soler, A | 1 |
| Burger, D; Clotet, B; Galindos, MJ; Gel, S; Miralles, C; Moltó, J; Muñoz-Moreno, JA; Negredo, E; Pedrol, E; Puig, J; Ribera, E; Rodriguez Fumaz, C; Rodríguez, E; Ruiz, L; Viciana, P; Videla, S | 1 |
| Blanco, JL; Gatell, JM; Laguno, M; León, A; Mallolas, J; Martinez, E; Pumarola, T | 1 |
| Ding, PP; Zhang, CY; Zheng, YH; Zhou, HY; Zou, W | 1 |
| García-Gibert, L; Giménez-Arnau, AM; Knobel, H; Montero, M | 1 |
| Baker, SG; Fitzmaurice, GM; Freedman, LS; Kramer, BS | 1 |
| Cui, WG; Dai, D; Diao, YY; Geng, WQ; Han, XX; Jiang, YJ; Liu, BG; Liu, J; Shang, H; Wang, Yn; Zhang, M; Zhang, ZN | 1 |
| Allavena, C; Arvieux, C; Bellein, V; Besnier, JM; Breux, JP; Ferré, V; Hascoet, C; Molina, JM; Raffi, F; Reliquet, V; Rozenbaum, W; Zucman, D | 1 |
| Cahn, P; Salomón, H; Zala, C | 1 |
| Blanco, JL; Crespo, M; Deig, E; Falcó, V; González, A; Miró, JM; Ocaña, I; Pahissa, A; Pedrol, E; Ribera, E; Rodríguez-Pardo, D; Rubio, M; Soler, A | 1 |
| Acosta, EP; Aldrovandi, G; Chen, J; Damle, B; Hodge, J; Hughes, MD; King, JR; Nachman, S; Wiznia, A; Yogev, R | 1 |
| Clark, R | 1 |
| Cao, YZ; Han, Y; Li, TS; Qiu, ZF; Wang, AX; Xie, J | 1 |
| Babudieri, S; Barreiro, P; Garcia-Samaniego, J; González-Lahoz, J; Maida, I; Martín-Carbonero, L; Mura, MS; Núñez, M; Ríos, MJ; Rivas, P; Soriano, V; Sotgiu, G; Toro, C | 1 |
| Allavena, C; Bellein, V; Besnier, JM; François-Brunet, C; Garré, M; May, T; Perré, P; Raffi, F; Reliquet, V; Souala, F | 1 |
| Chen, J; Ding, PP; He, Y; Li, H; Zhang, CY; Zheng, YH; Zhou, HY | 1 |
| Anastos, K; Cohen, M; Cole, S; Hessol, NA; Justman, J; Kaplan, RC; Lu, D; Shi, Q; Tien, PC; Vigen, C; Young, M | 1 |
| Asboe, D; Babiker, AG; Darbyshire, JH; Goodall, RL; Hooker, MH; Williams, IG | 1 |
| Abdoulaye, D; André, C; André, E; Bernard, L; Sandrine, PF; Sylvie, A | 1 |
| Antinori, A; Baxter, J; Cauda, R; Clevenbergh, P; Colafigli, M; De Luca, A; Giambenedetto, SD; Perno, CF; Prosperi, M; Ruiz, L; Trotta, MP | 1 |
| Alonzi, T; Ascenzi, P; Mancone, C; Narciso, P; Notari, S; Tripodi, M | 1 |
| Doerries, R; Drechsler, H; Gass, A; Hardmeier, M; Kuhle, J; Mehling, M; Ruegg, S | 1 |
| Basseila, GB; Bokilo, AD; Dokekias, AE; Galiba, FO; Malanda, F; Nsitou, MB; Ntsimba, P | 1 |
| Chen, Z; Gong, G; He, Y; Liu, C; Liu, M; Yin, W; Zheng, Y; Zhou, H | 1 |
| Karunaianantham, R; Narayanan, PR; Rajesh, L; Swaminathan, S | 1 |
| Achalapong, J; Ariyadej, S; Chotivanich, N; Collins, IJ; Cressey, TR; Frenkel, LM; Hemvuttiphan, J; Jarupanich, T; Jourdain, G; Kanchana, S; Kanjanasing, A; Kengsakul, K; Koetsawang, S; Lallemant, M; Le Coeur, S; Liampongsabuddhi, P; McIntosh, K; Ngo-Giang-Huong, N; Pornkitprasarn, W; Ratanakosol, J; Sabsanong, P; Sittipiyasakul, V; Sukhumanant, T; Traisaithit, P; Van Dyke, RB; Wannapira, W; Winiyakul, N | 1 |
| Cotton, MF; Rabie, H; van Zyl, GU | 1 |
| Delaporte, E; Diouf, A; Etard, JF; Girard, PM; Landman, R; Laurent, C; Molinari, N; Ndoye, I; Ngom Guèye, NF; Sow, PS; Tchatchueng Mbougua, JB | 1 |
| Chang, HM; Chen, YS; Lee, SS; Tsai, HC; Wann, SR | 1 |
| Côté, HC; Hukezalie, KR; Thumati, NR; Wong, JM | 1 |
| Chimukangara, B; Katzenstein, D; Manasa, J; Masimirembwa, C; Mitchell, R; Nyabadza, G | 1 |
9 review(s) available for nevirapine and didanosine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Antiretroviral therapy: a guide to the most important trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1997 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team.
Topics: Adult; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Multivariate Analysis; Nevirapine; Proportional Hazards Models; Viral Load; Zidovudine | 1999 |
[Antiretrovirals].
Topics: Acidosis, Lactic; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Hemophilia A; Hemorrhage; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Indinavir; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2003 |
The continuing evolution of HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Delayed-Action Preparations; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Monitoring; Emtricitabine; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Stavudine; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2003 |
Sex differences in antiretroviral therapy-associated intolerance and adverse events.
Topics: Acidosis, Lactic; Anti-Retroviral Agents; Didanosine; Exanthema; Female; HIV Infections; Humans; Liver Diseases; Male; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Randomized Controlled Trials as Topic; Sex Factors; Stavudine | 2005 |
Noncirrhotic portal hypertension associated with didanosine: a case report and literature review.
Topics: Aged, 80 and over; Antiretroviral Therapy, Highly Active; Ascites; Chemical and Drug Induced Liver Injury; Didanosine; Fatal Outcome; HIV Infections; HIV-1; Humans; Hypertension, Portal; Lamivudine; Male; Nevirapine; Portal Vein; Thrombosis; Tomography, X-Ray Computed | 2012 |
40 trial(s) available for nevirapine and didanosine
| Article | Year |
|---|---|
Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protoco
Topics: Adult; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Erythema; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 1996 |
Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.
Topics: Administration, Oral; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Male; Nevirapine; Pyridines; RNA, Viral; Viral Load; Zidovudine | 1997 |
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Therapy, Combination; HIV-1; Humans; Monitoring, Physiologic; Nevirapine; Phenotype; Prospective Studies; Pyridines; RNA, Viral; Viral Load; Zidovudine | 1997 |
A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; RNA, Viral; Viral Load; Zidovudine | 1998 |
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy.
Topics: Anti-HIV Agents; Australia; Canada; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Italy; Netherlands; Nevirapine; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 1998 |
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study T
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV; Humans; Male; Nevirapine; Placebos; Reverse Transcriptase Inhibitors; RNA, Viral; Survival Rate; Time Factors; Zalcitabine; Zidovudine | 1998 |
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Models, Biological; Nevirapine; Zidovudine | 1999 |
A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nevirapine; Zidovudine | 1999 |
Sequence clusters in human immunodeficiency virus type 1 reverse transcriptase are associated with subsequent virological response to antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Amino Acid Sequence; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Evolution, Molecular; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Nevirapine; Sequence Alignment; Time Factors; Viral Load; Zidovudine | 1999 |
Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.
Topics: Acquired Immunodeficiency Syndrome; Codon; Didanosine; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nevirapine; Polymerase Chain Reaction; Zidovudine | 2000 |
Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users.
Topics: Adult; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Methadone; Nevirapine; Pilot Projects; Prospective Studies; Substance Abuse, Intravenous; Viral Load | 1998 |
Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Female; HIV Infections; Humans; Male; Nevirapine; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine | 1998 |
Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team.
Topics: Adult; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Multivariate Analysis; Nevirapine; Proportional Hazards Models; Viral Load; Zidovudine | 1999 |
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Didanosine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Injections, Subcutaneous; Interleukin-2; Lamivudine; Lymphocyte Count; Male; Nelfinavir; Nevirapine; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 2000 |
Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Therapy, Combination; Giant Cells; HIV Infections; HIV-1; Humans; Nevirapine; RNA, Viral; Viral Load; Zidovudine | 2000 |
Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Nevirapine; Palatine Tonsil; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; T-Lymphocyte Subsets; Viral Load | 2000 |
Quality of life outcomes of combination zidovudine- didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nevirapine; Quality of Life; Reverse Transcriptase Inhibitors; Treatment Outcome; Zidovudine | 2000 |
The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome | 2000 |
Research study of combination AIDS therapies underway.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Humans; Lamivudine; Nevirapine; Pyridines; Zidovudine | 1996 |
Viramune triple combo reduces viral load below limit of detection.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; Randomized Controlled Trials as Topic; Viral Load; Zidovudine | 1997 |
New double vs. triple antiviral combination study, CD4 200-500, no prior treatment.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1995 |
Maintaining a low viral load with Nevirapine?
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 1998 |
Virus sidesteps convergent therapy.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Pyridines; Zidovudine | 1995 |
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.
Topics: Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Nevirapine; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Zidovudine | 2001 |
Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.
Topics: Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV Infections; HIV-1; Humans; Mutation; Nevirapine; Phenotype; Reverse Transcriptase Inhibitors; Zidovudine | 2001 |
Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Hydroxyurea; Male; Middle Aged; Nevirapine; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Viremia | 2002 |
Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV-1; Humans; Mutation; Nevirapine; Phenotype; Stavudine; Treatment Failure | 2002 |
Feeding risk cut for HIV-infected women.
Topics: Anti-HIV Agents; Breast Feeding; Didanosine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Risk Factors; Rwanda; Uganda; Zidovudine | 2003 |
Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lactates; Male; Middle Aged; Nelfinavir; Nervous System Diseases; Nevirapine; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Treatment Outcome | 2003 |
Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Chemical and Drug Induced Liver Injury; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Nevirapine; Organophosphonates; Pancreatitis; Patient Compliance; Quality of Life; RNA, Viral; Tenofovir | 2004 |
A one-year clinical trial using didanosine, stavudine and nevirapine for highly active antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Didanosine; Female; HIV-1; Humans; Immunophenotyping; Male; Middle Aged; Nevirapine; RNA, Viral; Stavudine; T-Lymphocytes | 2005 |
Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
Topics: Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Viral Load | 1999 |
Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nevirapine; Pilot Projects; RNA, Viral; Spain | 2005 |
Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Didanosine; Female; HIV Infections; HIV-1; Humans; Infant; Male; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Treatment Outcome | 2005 |
T-cell response of advanced aids patients after highly active antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-CD8 Ratio; CD8-Positive T-Lymphocytes; Didanosine; Female; Follow-Up Studies; Humans; Lymphocyte Count; Male; Middle Aged; Nevirapine; Stavudine; Viral Load | 2005 |
Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Female; Follow-Up Studies; France; HIV Infections; Humans; Male; Nevirapine; Stavudine; Treatment Outcome; Viral Load | 2006 |
A virological benefit from an induction/maintenance strategy: the Forte trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Resistance, Multiple, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Nelfinavir; Nevirapine; Patient Compliance; Remission Induction; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Time Factors; Treatment Failure; United Kingdom; Viral Load | 2007 |
[Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy for Chinese HIV-1 infected patients].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; China; Didanosine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome; Viral Load; Young Adult | 2009 |
Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; India; Lamivudine; Male; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Treatment Failure; Tuberculosis | 2009 |
Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Treatment Outcome; Viral Load; Zidovudine | 2011 |
103 other study(ies) available for nevirapine and didanosine
| Article | Year |
|---|---|
5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.
Topics: Anti-HIV Agents; Cell Line; HIV Reverse Transcriptase; Humans; Pyrimidines; Pyrimidinones; Reverse Transcriptase Inhibitors | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Synthesis and anti-HIV studies of 2-adamantyl-substituted thiazolidin-4-ones.
Topics: Animals; Anti-HIV Agents; Antineoplastic Agents; Cell Line; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Models, Molecular; Molecular Structure; Thiazolidinediones | 2007 |
Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 11: structural modulations of diaryltriazines with potent anti-HIV activity.
Topics: Anti-HIV Agents; Cell Line; HIV Reverse Transcriptase; HIV-1; Humans; Magnetic Resonance Spectroscopy; Molecular Structure; Quantitative Structure-Activity Relationship; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Electrospray Ionization; Triazines | 2008 |
Synthesis and anti-HIV studies of 2- and 3-adamantyl-substituted thiazolidin-4-ones.
Topics: Adamantane; Anti-HIV Agents; Cell Line; Cytostatic Agents; HIV-1; Humans; Molecular Conformation; Structure-Activity Relationship; Thiazolidines | 2009 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Nucleosides; Phenotype; Reverse Transcriptase Inhibitors | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Anti-HIV and antiplasmodial activity of original flavonoid derivatives.
Topics: Anti-HIV Agents; Antimalarials; Cell Line; Cell Survival; Flavonoids; HIV; HIV Infections; Humans; Malaria, Falciparum; Plasmodium falciparum | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazoles; Virus Replication | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
Topics: Binding Sites; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Protein Binding; Protein Structure, Tertiary; Pyrimidines; Pyrimidinones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2013 |
Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.
Topics: Aniline Compounds; Anti-HIV Agents; Drug Design; HIV-1; Humans; Models, Molecular; Piperidines; Structure-Activity Relationship | 2014 |
Jatrophane diterpenes as inhibitors of chikungunya virus replication: structure-activity relationship and discovery of a potent lead.
Topics: Alphavirus Infections; Antiviral Agents; Chikungunya Fever; Chikungunya virus; Diterpenes; Euphorbia; France; HIV-1; HIV-2; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Semliki forest virus; Sindbis Virus; Structure-Activity Relationship; Virus Replication | 2014 |
Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
Topics: Anti-HIV Agents; Catalytic Domain; Dose-Response Relationship, Drug; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Structure; Niacinamide; Protein Conformation; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured | 2014 |
Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Topics: Anti-HIV Agents; Binding Sites; Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2015 |
Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
Topics: Anti-HIV Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Nitrogen; Reverse Transcriptase Inhibitors; Solubility; Structure-Activity Relationship; Sulfones | 2015 |
Design, synthesis of new β-carboline derivatives and their selective anti-HIV-2 activity.
Topics: Carbolines; Drug Design; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Piperazines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2015 |
Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
Topics: Anti-HIV Agents; Chemistry Techniques, Synthetic; Computational Biology; Drug Design; HIV Reverse Transcriptase; HIV-1; Imidazoles; Molecular Docking Simulation; Protein Conformation; Pyrazines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2015 |
Antiviral Activity of Flexibilane and Tigliane Diterpenoids from Stillingia lineata.
Topics: Antiviral Agents; Chikungunya virus; Diterpenes; Euphorbiaceae; France; HCT116 Cells; HIV-1; HIV-2; Humans; Macrocyclic Compounds; MCF-7 Cells; Molecular Structure; Semliki forest virus; Sindbis Virus; Virus Replication | 2015 |
Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.
Topics: Anti-HIV Agents; Binding Sites; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Virus Replication | 2016 |
Design, synthesis and anti-HIV activity of novel quinoxaline derivatives.
Topics: Animals; Anti-HIV Agents; Chlorocebus aethiops; Computer Simulation; Drug Design; HIV Integrase; Molecular Docking Simulation; Quantitative Structure-Activity Relationship; Quinoxalines; Vero Cells | 2016 |
1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
Topics: Animals; Antiviral Agents; Cells, Cultured; Dogs; Dose-Response Relationship, Drug; HIV-1; Influenza A Virus, H1N1 Subtype; Madin Darby Canine Kidney Cells; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Uracil | 2016 |
Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells.
Topics: Acetamides; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Humans; Membrane Potential, Mitochondrial; Structure-Activity Relationship; Triazoles | 2016 |
Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
Topics: Anti-HIV Agents; Drug Stability; Esters; HIV-1; Humans; Inhibitory Concentration 50; Methane; Models, Molecular; Reverse Transcriptase Inhibitors | 2016 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays.
Topics: Anti-HIV Agents; Cell Line; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Discovery; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Microbial Sensitivity Tests; Molecular Structure; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Sulfones | 2017 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor.
Topics: Antiviral Agents; Benzodiazepines; Didanosine; Drug Synergism; Gene Products, tat; HeLa Cells; HIV; HIV Protease Inhibitors; Humans; Isoquinolines; Nevirapine; Pyridines; Pyrroles; Quinolines; Reverse Transcriptase Inhibitors; Saquinavir; tat Gene Products, Human Immunodeficiency Virus; Zalcitabine; Zidovudine | 1994 |
The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds.
Topics: Antiviral Agents; Cells, Cultured; Cytotoxicity Tests, Immunologic; Didanosine; Drug Interactions; HIV Reverse Transcriptase; HIV-1; Humans; Indolizines; Isoquinolines; Leukocytes, Mononuclear; Molecular Structure; Nevirapine; Pyridines; Quinolines; Reverse Transcriptase Inhibitors; Saquinavir; Uracil; Zalcitabine; Zidovudine | 1995 |
In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the Inter-Company Collaboration Protocol.
Topics: Antiviral Agents; Cell Line, Transformed; Cytopathogenic Effect, Viral; Didanosine; Drug Synergism; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Lamivudine; Nevirapine; Pyridines; Quinolines; Reverse Transcriptase Inhibitors; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
Topics: Acquired Immunodeficiency Syndrome; Biological Evolution; Didanosine; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nevirapine; Polymerase Chain Reaction; Pyridines; Pyridones; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Selection, Genetic; Virus Replication; Zidovudine | 1993 |
Triple whammy. Will an AIDS therapy live up to its advance billing?
Topics: Acquired Immunodeficiency Syndrome; Cells, Cultured; Didanosine; Drug Therapy, Combination; HIV; Humans; Nevirapine; Pyridines; Pyridones; Reverse Transcriptase Inhibitors; Virus Replication; Zidovudine | 1993 |
AIDS drugs. Harvard group makes a splash--twice.
Topics: Antiviral Agents; Didanosine; HIV; Mutation; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; Virus Replication; Zidovudine | 1993 |
Resisting the temptation.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Combinations; HIV; Humans; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Virus Replication; Zidovudine | 1993 |
Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
Topics: Base Sequence; Didanosine; DNA, Viral; Drug Resistance, Microbial; HeLa Cells; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutagenesis, Site-Directed; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zidovudine | 1993 |
[AIDS: therapeutic changes in the second decade. Triple combination--HIV vaccination].
Topics: Acquired Immunodeficiency Syndrome; AIDS Vaccines; Antiviral Agents; Cross-Sectional Studies; Didanosine; Drug Therapy, Combination; Germany; Humans; Incidence; Nevirapine; Pyridines; Zidovudine | 1993 |
Comparison of virus burden in blood and sequential lymph node biopsy specimens from children infected with human immunodeficiency virus.
Topics: Antiviral Agents; Biopsy; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; DNA, Viral; Drug Therapy, Combination; Female; HIV Core Protein p24; HIV Infections; HIV-1; Humans; In Situ Hybridization; Infant; Lymph Nodes; Male; Nevirapine; Pyridines; Viremia; Zidovudine | 1996 |
Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds.
Topics: Animals; Antiviral Agents; Didanosine; DNA, Viral; Enzyme-Linked Immunosorbent Assay; Fetal Tissue Transplantation; Flow Cytometry; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Liver Transplantation; Lymphocyte Count; Mice; Mice, SCID; Neutrophils; Nevirapine; Polymerase Chain Reaction; Pyridines; Rats; T-Lymphocytes; Thymus Gland; Transplantation, Heterologous; Zidovudine | 1996 |
[Nevirapine: a new principle of action against HIV].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Child; Clinical Trials as Topic; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Infant, Newborn; Male; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Pyridines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Time Factors; Zidovudine | 1996 |
Stavudine selectively induces apoptosis in HIV type 1-infected cells.
Topics: Anti-HIV Agents; Apoptosis; Cell Line; Didanosine; DNA Fragmentation; Down-Regulation; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reverse Transcriptase Inhibitors; Stavudine; T-Lymphocytes; Thymidine; Zalcitabine; Zidovudine | 1997 |
Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors.
Topics: Antiviral Agents; Cell Line; Cells, Cultured; Didanosine; Drug Interactions; Drug Resistance, Microbial; Drug Resistance, Multiple; Genotype; HIV-1; Humans; Lamivudine; Mutation; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; Virus Replication; Zidovudine | 1996 |
Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe.
Topics: Adult; Amino Acid Sequence; Base Sequence; Didanosine; DNA, Viral; Female; Genes, env; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Nevirapine; Nucleic Acid Heteroduplexes; Phylogeny; Pyridines; Reverse Transcriptase Inhibitors; Sequence Homology, Amino Acid; Zidovudine; Zimbabwe | 1997 |
Cure or control of HIV/AIDS?
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Models, Biological; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1997 |
Drugs for HIV infection.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates.
Topics: Anti-HIV Agents; Cell Line, Transformed; Cells, Cultured; Didanosine; Foscarnet; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Zidovudine | 1998 |
1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity.
Topics: Anti-HIV Agents; Cells, Cultured; Didanosine; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Nevirapine; Structure-Activity Relationship; Zidovudine | 1998 |
Induction-maintenance antiretroviral therapy: proof of concept.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 1998 |
Researchers report sustained suppression of HIV with nevirapine--didanosine--zidovudine.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors; Zidovudine | 1998 |
Rebound of plasma HIV viral load following prolonged suppression with combination therapy.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Male; Nevirapine; Reverse Transcriptase Inhibitors; Time Factors; Viral Load; Zidovudine | 1998 |
High incidence of nevirapine-associated rash in HIV-infected Chinese.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; China; Didanosine; Drug Eruptions; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 1998 |
Estimates of the virological benefit of antiretroviral therapy are both assay- and analysis-dependent.
Topics: Analysis of Variance; Anti-HIV Agents; Data Interpretation, Statistical; Didanosine; HIV Infections; HIV-1; Humans; Nevirapine; RNA, Viral; Statistics, Nonparametric; Time Factors; Viral Load; Zidovudine | 1998 |
Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Randomized Controlled Trials as Topic; Zidovudine | 1999 |
Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Randomized Controlled Trials as Topic; Viral Load; Zidovudine | 1999 |
Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.
Topics: Adult; Aging; Anti-HIV Agents; Didanosine; Follow-Up Studies; HIV Infections; HIV-1; Humans; Immunologic Memory; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Time Factors; Zidovudine | 1999 |
Changing cost of English HIV service provision 1996-1997. NPMS Steering Group. National Prospective Monitoring System.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Costs; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Hospital Costs; Humans; Nevirapine; RNA-Directed DNA Polymerase; United Kingdom; Zalcitabine; Zidovudine | 1999 |
Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Topics: Anti-HIV Agents; Cells, Cultured; Deoxycytidine; Didanosine; Drug Combinations; Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Molecular Structure; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; T-Lymphocytes; Thionucleosides; Zidovudine | 2000 |
[Cost effectiveness analysis of highly active antiretroviral therapy in HIV asymptomatic patients].
Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Didanosine; Drug Therapy, Combination; Female; HIV Seropositivity; Humans; Indinavir; Lamivudine; Male; Middle Aged; Nevirapine; Sickness Impact Profile; Spain; Stavudine; Viral Load; Zidovudine | 2000 |
Nevirapine plus didanosine: once or twice daily combination?
Topics: Administration, Oral; Adult; Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine | 2000 |
[Exanthema in a patient infected with the human immunodeficiency virus after starting antiretroviral treatment].
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Eruptions; HIV Infections; Humans; Male; Nevirapine; Reverse Transcriptase Inhibitors; Stavudine; Stevens-Johnson Syndrome | 2000 |
Leukocytopenia due to zidovudine- and nevirapine-containing regimens in elderly patients with HIV infection.
Topics: Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Drug Therapy, Combination; Fatal Outcome; Granulocyte Colony-Stimulating Factor; HIV Infections; HIV-1; Humans; Leukopenia; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Zidovudine | 2000 |
Resolution of chronic parvovirus b19-induced anemia, by use of highly active antiretroviral therapy, in a patient with acquired immunodeficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chronic Disease; Didanosine; Female; HIV Protease Inhibitors; Humans; Nelfinavir; Nevirapine; Parvoviridae Infections; Parvovirus B19, Human; Reverse Transcriptase Inhibitors; Treatment Outcome | 2001 |
Triple therapy in previously untreated patients reduces viral load below limit of detection.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Pyridines; Viral Load; Zidovudine | 1996 |
Two studies suggest nevirapine benefit for children.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pyridines; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 1997 |
Viramune triple therapy shows suppression of HIV after 1 year, 7 months.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Zidovudine | 1997 |
Protease inhibitor-sparing regimen suppresses HIV.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors; Stavudine | 1998 |
Nevirapine triple combo results released.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Erythema; HIV Infections; HIV-1; Humans; Nevirapine; Pyridines; Virus Replication; Zidovudine | 1995 |
Nevirapine: new drug, new class, new questions.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Didanosine; Drug Approval; Drug Therapy, Combination; HIV; HIV Infections; Humans; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration; Zidovudine | 1996 |
Nevirapine approved by FDA. Food and Drug Administration.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Approval; Drug Therapy, Combination; Female; HIV Infections; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pyridines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration; Viral Load; Zidovudine | 1996 |
NIAID researchers present new findings at retrovirus meeting. National Institute of Allergy and Infectious Diseases.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Chemokines; Clinical Trials as Topic; Clone Cells; Dendritic Cells; Didanosine; Disease Progression; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-10; Killer Cells, Natural; Lamivudine; Male; Nevirapine; Pyridines; Receptors, Cytokine; Reverse Transcriptase Inhibitors; Ritonavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Update on nevirapine: quest for a niche.
Topics: Adult; Anti-HIV Agents; Child; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Infant, Newborn; Nevirapine; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1997 |
Viral load--how low is best?
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 1998 |
Drugs for HIV infection.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dose-Response Relationship, Drug; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Saquinavir; Stavudine; Zidovudine | 2001 |
A simple, once-daily dosing regimen for treating HIV-1 infection in intravenous drug users.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Nevirapine; Pilot Projects; Polymerase Chain Reaction; RNA, Viral; Substance Abuse, Intravenous; Treatment Refusal; Viral Load | 2000 |
When will once (-a day) be enough?
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Didanosine; Emtricitabine; Humans; Hydroxyurea; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Zidovudine | 2000 |
Determinations of zidovudine/didanosine/nevirapine and zidovudine/didanosine/ritonavir in human serum by micellar electrokinetic chromatography.
Topics: Anti-HIV Agents; Chromatography, Micellar Electrokinetic Capillary; Didanosine; Humans; Nevirapine; Ritonavir; Zidovudine | 2002 |
Multiple relapses of human cytomegalovirus retinitis during HAART in an AIDS patient with reconstitution of CD4+ T cell count in the absence of HCMV-specific CD4+ T cell response.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cytomegalovirus Retinitis; Didanosine; Follow-Up Studies; Ganciclovir; HIV Protease Inhibitors; Humans; Lamivudine; Lymphocyte Activation; Male; Nevirapine; Recurrence; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2003 |
[A short-term trial of Didanosine, stavudine, and nevirapine combination therapy for human immunodeficiency virus infection].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Stavudine | 2003 |
Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Didanosine; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; Oxazines; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome | 2003 |
Mitochondrial effects of antiretroviral therapies in asymptomatic patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Base Sequence; Cross-Sectional Studies; Didanosine; DNA Primers; DNA, Mitochondrial; Female; HIV Infections; Humans; Lamivudine; Male; Mitochondria; Nelfinavir; Nevirapine; Polymerase Chain Reaction; Stavudine | 2004 |
Warning on two specific 3-drug regimens: Viread + Didanosine + either Sustiva or Viramune.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Organophosphonates; Oxazines; Tenofovir; United States; United States Food and Drug Administration | 2004 |
Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine.
Topics: Adenine; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir | 2005 |
[Toxic epidermal necrolysis associated with abacavir].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Dideoxynucleosides; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Nevirapine; Reverse Transcriptase Inhibitors; Stavudine; Stevens-Johnson Syndrome | 2005 |
Simple adjustments for randomized trials with nonrandomly missing or censored outcomes arising from informative covariates.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Humans; Likelihood Functions; Longitudinal Studies; Models, Statistical; Nevirapine; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Zalcitabine; Zidovudine | 2006 |
[Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China].
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Nevirapine; Oxazines; Stavudine; Viral Load | 2005 |
Treatment of primary HIV infection: a pilot study of stavudine and didanosine plus nevirapine with or without hydroxyurea.
Topics: Acute Disease; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Enzyme Inhibitors; HIV Infections; Humans; Hydroxyurea; Nevirapine; Pilot Projects; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome | 1999 |
Severe liver disease associated with prolonged exposure to antiretroviral drugs.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Ascites; Budd-Chiari Syndrome; Case-Control Studies; Didanosine; Female; Hemorrhage; HIV Infections; Humans; Liver Cirrhosis; Liver Diseases; Male; Middle Aged; Nevirapine; Spain; Stavudine; Time Factors; Transaminases | 2006 |
Evaluation of human immunodeficiency virus type 1-infected Chinese patients treated with highly active antiretroviral therapy for two years.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Didanosine; Female; HIV-1; Humans; Lymphocyte Activation; Male; Middle Aged; Nevirapine; Stavudine | 2007 |
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black People; Cholesterol; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Fasting; Female; Hispanic or Latino; HIV Infections; HIV Protease Inhibitors; HIV Seronegativity; HIV Seropositivity; HIV-1; Humans; Indinavir; Lamivudine; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Multivariate Analysis; Nelfinavir; Nevirapine; Organophosphonates; Ritonavir; Stavudine; Tenofovir; Triglycerides; United States; White People | 2007 |
Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect?
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injury; Didanosine; Female; HIV Infections; HIV-1; Humans; Hyperplasia; Liver; Liver Diseases; Liver Regeneration; Middle Aged; Nevirapine; Zidovudine | 2007 |
Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Female; Genotype; HIV Reverse Transcriptase; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mutation; Nelfinavir; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors; RNA, Viral; Salvage Therapy | 2007 |
Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration in human plasma by MALDI-TOF/TOF.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Monitoring; Feasibility Studies; Furans; Humans; Molecular Structure; Nevirapine; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Spectrophotometry, Ultraviolet; Stavudine; Sulfonamides | 2008 |
Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.
Topics: Adenine; Adult; AIDS Dementia Complex; Alkynes; Anti-HIV Agents; Anticonvulsants; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cerebrospinal Fluid; Cyclopropanes; Didanosine; HIV-1; Humans; Indinavir; Lamivudine; Male; Nelfinavir; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Seizures; Stavudine; Tenofovir; Viral Load; Virus Replication; Zidovudine | 2008 |
[Evaluation of antiretroviral therapy in HIV-infected adults in the Department of Haematology, University Hospital of Brazzavllle, Congo].
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Congo; Cyclopropanes; Didanosine; Drug Evaluation; Drug Therapy, Combination; Female; Hematology; HIV Infections; Hospital Departments; Hospitals, University; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Retrospective Studies; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Ligase Chain Reaction; Mutation, Missense; Nevirapine; Postpartum Period; Pregnancy; RNA, Viral; Sequence Analysis, DNA; Viral Load; Young Adult; Zidovudine | 2010 |
Another milestone in minimizing risks to mothers exposed to single-dose nevirapine for prevention of vertical transmission of HIV-1 to infants: what next?
Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Mutation, Missense; Nevirapine; Pregnancy; Zidovudine | 2010 |
In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Didanosine; Dideoxynucleosides; DNA Primers; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Telomerase; Tenofovir; Zidovudine | 2012 |
Community Based Antiretroviral Treatment in Rural Zimbabwe.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Community Health Centers; Cross-Sectional Studies; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Female; HIV-1; Humans; Lopinavir; Male; Middle Aged; Nevirapine; Ritonavir; Rural Population; Treatment Failure; Viral Load; Young Adult; Zimbabwe | 2017 |